273.37
전일 마감가:
$267.40
열려 있는:
$271.09
하루 거래량:
666.12K
Relative Volume:
0.74
시가총액:
$40.08B
수익:
$5.02B
순이익/손실:
$1.31B
주가수익비율:
30.68
EPS:
8.91
순현금흐름:
$1.56B
1주 성능:
+7.52%
1개월 성능:
+7.41%
6개월 성능:
+9.84%
1년 성능:
+30.47%
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
273.37 | 39.21B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
501.95 | 183.15B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
182.58 | 51.96B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
92.22 | 43.85B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
WST
West Pharmaceutical Services Inc
|
227.31 | 15.73B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2025-03-19 | 개시 | Morgan Stanley | Overweight |
2025-01-16 | 개시 | Goldman | Buy |
2025-01-10 | 개시 | Piper Sandler | Neutral |
2024-12-13 | 개시 | Stifel | Hold |
2024-09-24 | 개시 | Robert W. Baird | Outperform |
2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | 업그레이드 | Needham | Hold → Buy |
2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | 개시 | UBS | Buy |
2023-04-14 | 개시 | Mizuho | Buy |
2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-10-12 | 개시 | Jefferies | Hold |
2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | 개시 | Wolfe Research | Outperform |
2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-06-22 | 개시 | Robert W. Baird | Neutral |
2021-06-21 | 재확인 | Needham | Buy |
2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-03-16 | 업그레이드 | Needham | Hold → Buy |
2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | 개시 | CLSA | Underperform |
2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
2020-01-10 | 개시 | Oppenheimer | Perform |
2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
MIN and Resmed CDI: 2 ASX shares to dig into - Rask Media
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
What drives ResMed Inc. stock priceFree Investment Timing Strategies - jammulinksnews.com
ResMed Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
What analysts say about ResMed Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is ResMed Inc. a good long term investmentMarket-beating returns - jammulinksnews.com
ResMed stock hits 52-week high at 263.62 USD By Investing.com - Investing.com South Africa
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® - GlobeNewswire Inc.
Published on: 2025-07-19 18:08:41 - jammulinksnews.com
What makes ResMed Inc. stock attractive to long term investorsTrend Based Entry Alerts - beatles.ru
This ResMed Insider Reduced Their Stake By 72% - simplywall.st
This Pick Withstood the GLP-1 Challenge. Stick With the Stock. - Barron's
Analyst Expectations For ResMed's Future - Nasdaq
ResMed (RMD) Price Target Increased to $270 by Mizuho Analyst | - GuruFocus
Brokers Set Expectations for ResMed's Q1 Earnings (NYSE:RMD) - MarketBeat
RBC Upgrades ResMed to Outperform From Sector Perform, Adjusts Price Target to $294 From $255 - MarketScreener
ResMed's Trading Volume Surges 78.7% to 2.35 Billion, Stock Price Drops 0.11% Placing 406th in Market Rankings - AInvest
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - 富途牛牛
ResMed CEO Executes Stock Transactions Under Rule 10b5-1 Plan - TipRanks
Resmed CEO Farrell sells $2.06 million in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $2,056,076, According to a Recent SEC Filing - MarketScreener
ResMed Inc. Officer Plans Sale of Common Stock Under Rule 144 - TipRanks
With 75% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - simplywall.st
ResMed CFO Reports Changes in Stock Ownership - TipRanks
ResMed to Release Q4 2025 Financial Results on July 31, 2025, via Webcast - AInvest
ResMed Executives Sell Shares Under Pre-arranged Trading Plans - TradingView
ResMed Director Announces Further Share Sale - TipRanks
ResMed Chief Legal Officer Sells Shares - MarketScreener
Resmed Inc Officer Files Notice for Stock Sale Under Rule 144 - TipRanks
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 | RMD Stock News - GuruFocus
Resmed Announces Fourth Quarter Fiscal Year 2025 Financial Results Release and Webcast Details - Quiver Quantitative
ResMed (NYSE:RMD) Shows Growth in ROCE and Business Efficiency NYSE Composite - Kalkine Media
ResMed (NYSE:RMD) Could Become A Multi-Bagger - Yahoo Finance
Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed - Yahoo Finance
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy - Yahoo Finance
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
ResMed Stock: Is RMD Outperforming The Healthcare Sector? - Barchart.com
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com
ResMed CEO Sells Shares Worth $2 Million - MarketScreener
ResMed Inc Reports Change in Beneficial Ownership - TipRanks
ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Resmed Inc 주식 (RMD) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Farrell Michael J. | Chief Executive Officer |
Jul 07 '25 |
Sale |
256.72 |
8,009 |
2,056,076 |
455,503 |
자본화:
|
볼륨(24시간):